Skip to content

PressReach

SEARCH icon
  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos
Search

SEARCH FOR AN ARTICLE

  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos

PressReach

icon

      HomeBiotech

      Biotech

      Profusa Announces Signing of Option Agreement for the  Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs
      Biotech

      Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs

      July 31, 2026
      Apnimed Announces Pricing of Upsized Initial Public Offering
      Biotech

      Apnimed Announces Pricing of Upsized Initial Public Offering

      July 30, 2026
      Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
      Biotech

      Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

      July 30, 2026
      Amneal Reports Second Quarter 2026 Financial Results
      Biotech

      Amneal Reports Second Quarter 2026 Financial Results

      July 30, 2026
      Fortrea Reports Second Quarter 2026 Results
      Biotech

      Fortrea Reports Second Quarter 2026 Results

      July 29, 2026
      AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
      Biotech

      AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

      July 29, 2026
      AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
      Biotech

      AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

      July 29, 2026
      ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
      Biotech

      ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

      July 28, 2026
      IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers
      Biotech

      IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

      July 27, 2026
      Legend Biotech Announces CEO Transition
      Biotech

      Legend Biotech Announces CEO Transition

      July 27, 2026
      1 2 3 … 150 »

       

      LATEST NEWS

      • Health Sanofi Market Potential Boosted by Amvuttra Data

      PressReach

      All logos, trade names and/or trademarks, artwork and associated imagery are trademarks and/or copyright material of their respective owners.

      • Advertisers
      • Privacy Policy
      • Terms of Use
      • DMCA Policy
      • Disclaimer
      • Contact Us

      SUBSCRIBE

      To get email updates from PressReach.

      I want e-mail alerts, updates, and offers and agree to the PressReach privacy policy.

      Market Jar Media Inc. © 2026